How does genetic polymorphism affect Alzheimer’s treatments?

This key study explores the influence of CYP2C9 genetic polymorphisms on the pharmacokinetics (PK) of delta-9-tetrahydrocannabinol (THC) and its active metabolites in Alzheimer’s disease (AD) patients.

Titled ‘A study on CYP2C9 polymorphism, in Puerto Rican Alzheimer’s patients and its role in the Pharmacokinetics of ∆-9-tetrahydrocannabinol,’ it is accessible at the European Society of Medicine website.

The research highlights the critical role of CYP2C9 polymorphisms in THC metabolism, highlighting significant variations in the half-life of THC and OH-THC among different CYP2C9 phenotypes. These findings suggest the necessity for personalized dosing strategies to enhance treatment efficacy and safety for Alzheimer’s patients.

Understanding CYP2C9 polymorphisms in Alzheimer’s treatments

Ram Mukunda, CEO of IGC Pharma, said: “We are thrilled to share this significant publication in the European Society of Medicine journal. This research exemplifies our dedication to advancing Alzheimer’s​ treatment through innovative science. Understanding genetic influences on drug metabolism is vital for developing safe and effective therapies.”

Conducted with a Puerto Rican cohort, the study aligns with IGC Pharma’s commitment to inclusive clinical research. Puerto Rico was strategically selected due to its higher Alzheimer’s prevalence of 12% compared to the continental US rate of 10.7%, ensuring comprehensive data collection and improved therapy accessibility.

IGC Pharma’s leading candidate, IGC-AD1, was tested in a phase 1 multiple ascending dose (MAD) trial. The study’s outcomes support the potential for personalized medicine approaches in treating Alzheimer’s.

Leave a Reply

Your email address will not be published. Required fields are marked *